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Dihydroartemisinin-piperaquine (DHP) is an important new treatment for drug-resistant malaria, although
pharmacokinetic studies on the combination are limited. In Papua, Indonesia, we assessed determinants of the
therapeutic efficacy of DHP for uncomplicated malaria. Plasma piperaquine concentrations were measured on
day 7 and day 28, and the cumulative risk of parasitological failure at day 42 was calculated using survival
analysis. Of the 598 patients in the evaluable population 342 had infections with Plasmodium falciparum, 83
with Plasmodium vivax, and 173 with a mixture of both species. The unadjusted cumulative risks of recurrence
were 7.0% (95% confidence interval [CI]: 4.6 to 9.4%) for P. falciparum and 8.9% (95% CI: 6.0 to 12%) for P.
vivax. After correcting for reinfections the risk of recrudescence with P. falciparum was 1.1% (95% CI: 0.1 to
2.1%). The major determinant of parasitological failure was the plasma piperaquine concentration. A concen-
tration below 30 ng/ml on day 7 was observed in 38% (21/56) of children less than 15 years old and 22% (31/140)
of adults (P  0.04), even though the overall dose (mg per kg of body weight) in children was 9% higher than
that in adults (P < 0.001). Patients with piperaquine levels below 30 ng/ml were more likely to have a
recurrence with P. falciparum (hazard ratio [HR]  6.6 [95% CI: 1.9 to 23]; P  0.003) or P. vivax (HR  9.0
[95% CI: 2.3 to 35]; P  0.001). The plasma concentration of piperaquine on day 7 was the major determinant
of the therapeutic response to DHP. Lower plasma piperaquine concentrations and higher failure rates in
children suggest that dose revision may be warranted in this age group.
The emergence of multidrug-resistant strains of Plasmodium
falciparum and, more recently, Plasmodium vivax poses a sig-
nificant threat to the 40% of the global population at risk of
malaria (13, 20). Following World Health Organization
(WHO) recommendations, more than 60 countries are now
moving towards deploying artemisinin combination therapies
to improve antimalarial efficacy and minimize the selection of
drug-resistant parasites. However, debate still continues as to
the most effective combination and how these new treatments
should be deployed and funded.
Dihydroartemisinin-piperaquine (DHP) is a novel fixed-
dose combination that is gaining a reputation as an important
addition to the artemisinin combination therapy pharmaco-
poeia, particularly in areas with high levels of antimalarial drug
resistance. The antimalarial activity of piperaquine has been
recognized since the 1960s, although its widespread use in
clinical practice has been restricted mainly to the People’s
Republic of China, where it replaced chloroquine in the na-
tional malaria control program in 1978 (4), and more recently
Vietnam. In the last 5 years there has been an evolving body of
evidence demonstrating excellent efficacy of DHP against mul-
tidrug-resistant strains of P. falciparum (1, 5, 7, 12, 15, 19, 22)
and P. vivax (7, 15).
In Papua, Indonesia, where drug resistance has emerged in
both P. falciparum and P. vivax (16), we have recently con-
ducted two clinical drug studies with DHP. In both studies, the
combination was found to be well tolerated and more effective
at reducing recurrent malaria within 42 days than the compar-
ator treatment arms (amodiaquine plus artesunate or arte-
mether-lumefantrine) (7, 15). In this paper we have pooled
these studies and incorporated measures of plasma pipera-
quine concentrations to assess the clinical and pharmacological
parameters associated with the therapeutic response.
MATERIALS AND METHODS
Study site. The data used for this analysis were derived from two comparative
studies conducted between April 2004 and December 2005, in two rural outpa-
tient clinics, in the Timika district of southern Papua, Indonesia (7, 15). The
annual incidence of malaria in the region is approximately 900 per 1,000 per year,
divided 57:43 between P. falciparum and P. vivax infections (our unpublished
data). Due to economic migration the ethnic origin of the local population is
diverse, with highland Papuans, lowland Papuans, and non-Papuans resident in
the region.
* Corresponding author. Mailing address: Menzies School of Health
Research, PO Box 41096, Casuarina, Darwin, NT 0811, Australia.
Phone: (61) 8 8922 8197. Fax: (61) 8 8922 8429. E-mail: ricprice
@doctors.org.uk.
 Published ahead of print on 10 September 2007.
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Study design. These prospective open-label randomized comparative trials
administered DHP for the treatment of infections with P. falciparum or P. vivax
in children and adults with uncomplicated symptomatic malaria. The studies
were based on the 2003 WHO in vivo antimalarial drug sensitivity protocol,
modified to include mixed infections and any level of parasitemia. Patients were
followed for 42 days using a standardized drug efficacy record form.
Patients. Patients with slide-confirmed malaria (P. falciparum, P. vivax, or
mixed infections) and fever or a history of fever during the 48 h preceding
presentation to the outpatient clinic were eligible for enrolment. Pregnant or
lactating women and children under 5 kg were excluded, as were patients with
WHO danger signs or signs of severity, a parasitemia of 4% of infected red
blood cells, or concomitant disease requiring hospital admission.
Study procedures. After enrolment a standardized data sheet was completed
recording demographic information, details of symptoms and their duration, and
the history of previous antimalarial medication. Clinical examination findings
were documented, including the axillary temperature, which was measured using
a digital thermometer. Venous blood was taken for blood film, hematocrit,
hemoglobin, and white cell count. Parasite counts were determined on Giemsa-
stained thick films as the number of parasites per 200 white blood cells, and
peripheral parasitemia was calculated assuming a white cell count of 7,300 l1.
Hemoglobin level was measured using a battery-operated portable photometer
(Hb201; HemoCue, Angelholm, Sweden). Blood spots on filter paper (What-
man; BFC 1802) were also collected on day 0.
DHP (Artekin; Holley Pharmaceutical Co., People’s Republic of China; con-
taining 40 mg dihydroartemisinin and 320 mg piperaquine) was administered as
a weight-per-dose regimen of 2.25 and 18 mg/kg of body weight per dose of
dihydroartemisinin and piperaquine, respectively, rounded up to the nearest half
tablet. Children under 9 kg were dosed with a suspension made by crushing one
tablet in 5 ml of water (i.e., 8 mg DHA and 64 mg piperaquine per ml). Tablets
for both studies came from the same batch, which was manufactured in February
2004, with an expiry date of February 2007. All doses were supervised and
administered on admission and 24 and 48 h after admission. When drug admin-
istration was observed and vomiting occurred within 60 min, administration of
the full dose was repeated. Primaquine (0.3 mg of base/kg of body weight for 14
days) was administered unsupervised to those individuals with P. vivax infection
or mixed infection.
Patients were examined daily after enrolment until they became afebrile and
aparasitemic. At each visit a blood smear was taken and a symptom question-
naire completed. Patients were then seen weekly for 6 weeks. At each clinic
appointment a full physical examination was performed, the symptom question-
naire was completed, and blood was taken to check for parasite count and
hemoglobin. Blood spots on filter paper were also collected on the day of failure.
On days 7 and 28, 10 ml of blood was collected from patients who agreed to
venipuncture. Samples were spun down within 2 h and stored at 80°C until
processing. Plasma piperaquine concentrations were determined by high-perfor-
mance liquid chromatography with UV detection (11); the lower level of quan-
tification was 2.5 ng/ml, with an interassay coefficient of variation of 8.4% at
20 ng/ml.
Statistical analysis. Data were double entered and validated using EpiData
3.02 software (EpiData Association, Odense, Denmark), and analysis was per-
formed using SPSS for Windows (version 15; SPSS Inc., Chicago, IL). The
Mann-Whitney U test, Kruskal-Wallis method, or Spearman’s rank correlation
FIG. 1. Study profile.
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was used for nonparametric comparisons, and Student’s t test or one-way analysis
of variance was used for parametric comparisons. Proportions were examined
using 2 with Yates’ correction or Fisher’s exact test. The influence of the date
of enrolment on treatment efficacy was investigated by categorizing patients
according to four 4-month periods over the 16-month period of the study.
Efficacy end points were assessed using survival analysis. All patients meeting
the enrolment criteria were included in the evaluable population. Results for
anyone failing to complete follow-up were censored on the last day of follow-up
and were regarded as not representing a treatment failure. In patients with P.
falciparum alone or mixed infections in both the initial and recurrent para-
sitemia, reinfections and recrudescent infections were determined by PCR ac-
cording to polymorphisms in MSP-1, MSP-2, and GLURP as described previ-
ously (3). Failure rates were defined by the cumulative incidence at day 42
calculated by the Kaplan-Meier method. The risks of treatment failure were
compared by the Mantel-Haenszel log rank test, and the hazard ratio (HR) was
presented. In the multivariable analysis any variables found to be associated
significantly with the dependent variable in univariate analysis were entered into
a Cox regression model and the model was constructed using all factors.
Since the relationship of the therapeutic response and plasma concentrations
of antimalarial drugs is nonlinear (23), plasma piperaquine concentrations on
day 7 were dichotomized using the receiver operator curve, and the optimal
cutoff was defined as the maximum value of Youden’s index (sensitivity plus
specificity minus 1). The terminal elimination half-life was derived from the
elimination rate constant, calculated from plasma piperaquine concentrations on
day 7 and day 28 by log-linear interpolation.
Ethics. The study was approved by the ethics committee of the National
Institute of Health Research and Development, Indonesian Ministry of Health
(Jakarta, Indonesia), the ethics committee of the Menzies School of Health
Research (Darwin, Australia), and the Oxford Tropical Research Ethics Com-
mittee (United Kingdom). Written informed consent was obtained from adult
patients and parents of enrolled children. The trials were registered with the
clinical trial website (http://www.clinicaltrials.gov/ct) as NCT 00157833 and NCT
00157885.
RESULTS
Between July 2004 and November 2005, 608 patients with
uncomplicated malaria were enrolled in two comparative drug
studies and treated with DHP. In total, 10 protocol violations
were identified within 24 h; the patients involved were offered
alternative treatment and excluded from further analysis (Fig.
1). Of the remaining 598 patients, 342 (57%) had pure P.
falciparum infection, 83 (14%) had P. vivax infection, and 173
(29%) had both species present. Baseline characteristics are
given in Table 1. Follow-up to day 42 or day of failure was
achieved in 71% (424/598) of patients. Six patients (1.0%)
were unable to tolerate their medication due to recurrent vom-
iting and required rescue treatment. The early therapeutic
response in the remaining patients was rapid and within 48 h
99% of patients were aparasitemic (563/569) and afebrile
(523/526).
TABLE 1. Patient characteristics at baseline
Parameter
Value for:
Evaluable population Subset of patients with plasmapiperaquine measurementsa
Total no. of patients 598 229
P. falciparum infection at enrolment
No. (%) of patients 342 (57) 136 (59)
Geometric mean parasitemia
(organisms/l1) (95% CI)
3,848 (3,198–4,632) 3,631 (2,758–4,782)
No. (%) of patients with parasitemia
1,000 organisms l1
275 (80) 111 (82)
P. vivax infection at enrolment
No. of patients (%) 173 (29) 51 (22)
Geometric mean parasitemia (organisms
l1) (95% CI)
1,988 (1,550–2,550) 1,794 (1,168–2,757)
No. (%) of patients with parasitemia
400 organisms l1
136 (79) 42 (82)
Mixed infections at enrolment
No. (%) of patients 83 (14) 42 (18)
Geometric mean parasitemia (organisms
l1) (95% CI)
4,717 (3,399–6,547) 5,175 (3,269–8,193)
No. (%) of patients with parasitemia
400 organisms l1
79 (95) 40 (95)
No. (%) of males 349 (58) 145 (63)
Median wt (kg) (range) 46 (7–85) 52 (11–80)*
Median age (yr) (range) 16 (1–60) 20 (3–60)*
No. (%) of patients aged
5 yr 96 (16) 4 (1.7)
5–14 yr 178 (30) 61 (27)
14 yr 324 (54) 164 (72)
No. (%) of patients with temp 37.5°C 136 (23) 53 (23)
No. (%) of patients with history of malaria
in previous mo
141 (24) 45 (20)
Mean hemoglobin level (g/dl) (SD) 10.2 (2.5) 10.9 (2.4)*
No. (%) of patients with splenomegaly 402 (67) 139 (61)
a , significant difference (P  0.001) between subset of patients with plasma piperaquine measurement and the whole cohort.
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Treatment failure. Early clinical deterioration with danger
signs was observed within 24 h in three patients, who were
transferred to hospital and treated with intravenous quinine.
By day 42, a further 60 patients had had a recurrent para-
sitemia (Fig. 1), with an overall cumulative risk of treatment
failure of 15% (95% confidence interval [CI]: 12 to 19%). In
total, 53% (30/57) of patients with recurrences were symptom-
atic, 12% (7/57) had documented fever, and 23% (11/47) were
anemic (hemoglobin  10 g/dl). There were no significant
differences in these proportions between the species at the
time of recurrence. By day 42 the cumulative risks of recur-
rence were 7.0% (95% CI: 4.7 to 9.35%) for P. falciparum and
8.9% (95% CI: 6.0 to 12%) for P. vivax. After PCR correction
the cumulative risk of recrudescent P. falciparum fell to
1.1% (95% CI: 0.1 to 2.1%). In those patients failing treat-
ment the median time to recurrence with P. falciparum was
36 days (range, 22 to 45 days) compared to 43 days (range,
22 to 45 days) for patients failing with pure P. vivax (P 
0.04).
Clinical risk factors for treatment failure. Four univariate
factors on admission were associated with treatment failure:
the species of the initial infection, being an indigenous Papuan
(HR  4.7; 95% CI: 1.7 to 13; P  0.003), having diarrhea at
presentation (HR  1.9; 95% CI: 1.1 to 3.1; P  0.014), and
prior treatment for malaria within the preceding month (HR
1.7; 95% CI: 1.0 to 2.9; P  0.039). The overall cumulative risk
of failure was 10.1% (95% CI: 6.2 to 14.0%) in patients pre-
senting initially with P. falciparum infections, compared to
19.4% (95% CI: 12 to 26.8%) in patients infected with P. vivax
and 27.3% (95% CI: 16.2 to 38.5%) in those with mixed infec-
tions; the overall P value was 0.001. In a multivariable model
including all patients enrolled, after stratifying by the initial
species of infection, the only significant risk factor for treat-
ment failure was Papuan ethnicity (adjusted hazards ratio
[AHR]  5.0; 95% CI: 1.8 to 14; P  0.002). The risk of
recurrent parasitemia with P. vivax was 7.3% (95% CI: 4.4 to
10.2%) in children under 5 years old, compared to 17.0% (95%
CI: 7.6 to 26.4%) in older children and adults (HR  2.5; 95%
CI: 1.2 to 5.1; P  0.012). There was no significant difference
in the cumulative risk of reappearance for P. falciparum be-
tween age groups. The risk of failure did not differ with sex,
vomiting of medication, or baseline parasitemia. And there was
not a significant difference or discernible trend in either the
cumulative risk of treatment failure at day 42 or the speed of
parasite clearance between patients recruited at the start and
end of the study period.
FIG. 2. Scatter plots of weight (a) and age (b) with the mg/kg dose of piperaquine administered.
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Dose of DHP. The mean total dose of dihydroartemisinin
administered was 6.75 mg/kg (95% CI: 6.68 to 6.82 mg/kg;
range: 4.62 to 9.23 mg/kg) and that of piperaquine was 54.0
mg/kg (95% CI: 53.4 to 54.6 mg/kg; range: 36.9 to 73.9 mg/kg)
(Fig. 2a). Neither the dose of dihydroartemisinin nor that of
piperaquine correlated with the speed of clearance of periph-
eral parasitemia. The mean dose of piperaquine administered
to children under 5 years old was 55.4 mg/kg (95% CI: 52.8 to
58.1 mg/kg) compared to 56.9 mg/kg (95% CI: 55.9 to 57.9
mg/kg) in children aged 5 to 15 years and 51.9 mg/kg (95% CI:
51.6 to 52.2 mg/kg) in adults (overall P 0.001). The spread of
dosing was greatest in children under 5 years old (standard
deviation [SD]  12.7 mg/kg) compared to children aged 5 to
15 years (SD  6.8 mg/kg) and adults (SD  2.8 mg/kg) (Fig.
2b). Using Youden’s index the best cutoff for the total pipera-
quine dose predicting treatment failure was 48 mg/kg, with
46% (42/92) of children under 5 years of age receiving a dose
of piperaquine below this level compared to 8.1% (14/173) of
children aged 5 to 14 years and 12.9% (39/263) of adults
(overall P  0.001). The overall risk of failure was 31% (95%
CI: 20 to 42%) in patients administered less than 48 mg/kg
compared to 9.0% (95% CI: 6.1 to 11.9%) in those receiving
higher doses (HR  3.1; 95% CI: 1.9 to 5.2; P  0.001).
Piperaquine levels. Plasma piperaquine levels were available
for 33% (196/598) of patients on day 7 and 18% (109/598) on
day 28 (Fig. 1). Overall, 51% (164/324) of adults agreed to
venipuncture compared to 34% (61/178) of parents of children
aged 5 to 14 years and only 4% (4/96) of parents of children
under 5 years of age (P  0.001). Compared to those refusing
venipuncture, patients with available plasma concentrations
did not differ in parasite density, ethnic group, diarrhea on
admission, or risk of recurrence by day 42 (Table 1).
The mean plasma piperaquine concentration was 46.6 ng/ml
(95% CI: 43.3 to 49.8 ng/ml) on day 7 and 16.8 ng/ml (95% CI:
15.1 to 18.6 ng/ml) on day 28. Age and the plasma concentra-
tion of piperaquine on day 7 were positively correlated (rs 
0.289; P 0.001) (Fig. 3), with day 7 concentrations 26% lower
in children aged less than 15 years (mean  37.1 ng/ml; 95%
CI: 32.8 to 41.3 ng/ml) than in adults (mean 50.4 ng/ml; 95%
CI: 46.4 to 54.5 ng/ml; P  0.001).
In total 73 patients had levels on both day 7 and day 28, 4 of
whom had undetectable levels on the second measurement.
In those with detectable levels on both days the mean elim-
ination half-life was estimated as 16.5 days (95% CI: 11.5 to
21.5 days), with no differences between adults (n  52) and
children (n  17).
In patients with recurrent parasitemia, the mean plasma
piperaquine level on day 7 was 28.4 ng/ml (95% CI: 22.1 to 34.8
ng/ml), compared to 48.7 ng/ml (95% CI: 45.3 to 52.1 ng/ml) in
those treated successfully (P 0.001). The best cutoff for the day
7 piperaquine concentration predicting any treatment failure was
30 ng/ml, with levels below this observed in 38% (21/56) of chil-
dren and 22% (31/140) of adults (relative risk [RR]  1.69; 95%
CI: 1.1 to 2.7; P  0.04). In the 196 patients with available day 7
piperaquine concentrations, the overall the risk of failure was
36% (95% CI: 20 to 52%) in patients with concentrations below
this level compared to 6.8% (95% CI: 1.9 to 12%) in those above
(HR  6.1; 95% CI: 2.4 to 15.5; P  0.001) (Fig. 4). The risks of
failure stratified by species are given in Table 2.
Piperaquine concentrations below 30 ng/ml on day 7 were
significantly more likely to occur in patients who were Papuan
(RR 5.2; 95% CI: 1.7 to 15.8; P 0.001), who were less than
15 years old (RR  1.7; 95% CI: 1.1 to 2.7; P  0.04), or who
presented with diarrhea (RR  1.8; 95% CI: 1.2 to 2.9; P 
0.02) or anemia (RR  2.3; 95% CI: 1.5 to 3.6; P  0.001). In
a multivariable model including all these factors and stratifying
by the initial species, the only significant risk factor predicting
recurrent parasitemia was a day 7 concentration below 30
ng/ml (AHR  5.1; 95% CI: 1.6 to 16; P  0.001). The overall
population attributable risk associated with low piperaquine
concentration at day 7 was 21%.
DISCUSSION
The results of our studies demonstrate that DHP is well
tolerated and a highly effective treatment of both multidrug-
FIG. 3. Scatter plot of age and the plasma piperaquine concentration on day 7 (rs  0.289; P  0.001). The dashed line represents the 30-ng/ml
cutoff, found to be the best predictor of treatment failure.
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resistant P. falciparum and P. vivax in Papua, Indonesia. Of the
99% of patients who completed their course of treatment, the
cumulative risk at day 42 of true recrudescence with P. falcip-
arum was 1.1%, with a corresponding risk of recurrence with P.
vivax of 8.9%. However, despite these excellent results we
identified certain groups of patients at significantly greater risk
for recurrence of malaria, in whom the risk of treatment failure
rose to as high as 50%.
Artemisinin combination therapies achieve their antimalar-
ial effect through an initial rapid reduction in parasite biomass,
attributable to the short-acting but highly potent dihydroarte-
misinin, with the subsequent removal of the remaining para-
sites by the intrinsically less active but more slowly eliminated
piperaquine. Overall cure rates depend upon there being suf-
ficient partner drug to remove the residual parasite biomass
left by the artemisinin derivative. Our venous sampling was
pragmatic, but sparse and therefore did not allow us to define
the full pharmacokinetic profile of piperaquine. However, as
with other long-acting antimalarial drugs, the day 7 level may
provide a useful surrogate marker of the area under the curve
and time above the MIC (6, 18), both crucial determinants of
the in vivo response to antimalarial drugs (23). Studies with
both artemether-lumefantrine and mefloquine plus artesunate
have shown that the day 7 concentrations of the long-acting
partner drug are the primary predictors of subsequent treat-
ment outcome (14, 18).
In the present study we show that two pharmacological pa-
rameters, the day 7 piperaquine concentration and the total
mg/kg dose of piperaquine administered, were important de-
terminants of treatment outcome. Children were more vulner-
able to both inadequate dosing and low plasma drug concen-
trations. Even though the dose of DHP was administered on
the basis of weight, this was carried out according to weight
groups to the nearest half tablet, with a suspension used only
for those weighing less than 9 kg. This strategy amounted to
increments in dose of 160 mg of piperaquine and 20 mg of
FIG. 4. Cumulative risk of patients failing with any parasitemia. Circles, day 7 piperaquine concentration of 30 ng/ml; diamonds, day 7
piperaquine concentration of 30 ng/ml. The overall P value for the difference between treatment groups at day 42 was 0.001.
TABLE 2. Day 42 cumulative risk of failure following DHP in 198 patients with available plasma piperaquine concentrations on day 7
Parasitological failure
Day 7 piperaquine
concn  30 ng/ml
Day 7 piperaquine
concn  30 ng/ml HRa (95% CI); P
n Risk (%) (95% CI) n Risk (%) (95% CI)
Any species after initial infection with any species 52 36 (20–52) 144 6.8 (1.9–12) 6.1 (2.4–15); 0.001
P. falciparum
After initial infection with any species 52 23 (9.6–37) 144 3.8 (0.1–7.5) 6.6 (1.9–23); 0.003
True recrudescence of P. falciparumb 44 6.1 (0–14.5) 106 0 0.02c
After reinfection with P. falciparum 52 18 (4.7–31) 144 3.8 (0.1–7.5) 4.9 (1.3–18); 0.017
P. vivax
After initial infection with any species 52 26 (10–42) 144 3.1 (0–6.6) 9.0 (2.3–35); 0.001
After initial infection with P. vivax
(alone or mixed)
23 50 (21–79) 60 4.8 (0–11) 11.6 (2.3–57); 0.003
a The HR was calculated using a Cox regression model after stratifying for the initial species of infection.
b After correcting by PCR genotyping, in patients initially infected with P. falciparum (alone or mixed).
c Value for P.
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dihydroartemisinin, and the effects of such an increase resulted
in a wide range in the mg/kg dose administered, particularly in
young children (Fig. 2). Although this variability would be
ameliorated by the wider use of pediatric syrup or suspensions,
such formulations are not yet available for many antimalarials.
Furthermore, in practice most rural clinics administer drugs
according to age groups, with inevitable inaccuracies in dosing
(21). These findings highlight the need for practical attention
to, and reporting of, dosing practices, particularly in young
children.
We were not able to define the relevance of inadequate
dosing on plasma levels of piperaquine, since parents of only
four children under 5 years of age agreed for their children to
be bled. However, in older children the overall mean dose
administered to children was actually 9% higher than that
given to adults and yet the day 7 plasma piperaquine concen-
trations were 26% lower. This discrepancy could have arisen
from higher clearance rates, which have been noted in children
(9). Our estimate of the terminal elimination half-life of pip-
eraquine was 396 h, similar to that observed previously (9),
although no difference in half-life between adults and children
aged 5 to 14 years was noted. An alternative explanation is that
the low plasma concentrations of piperaquine are a conse-
quence of inadequate drug absorption, to which children are
particularly vulnerable, especially those presenting with diar-
rhea. Since coadministration with a high-fat meal increases the
oral bioavailability of piperaquine by 120% (17), advocating
that medication be taken with a glass of milk or a biscuit, as is
currently recommended for artemether-lumefantrine, may
help to improve piperaquine absorption.
Young children were 2.5-fold more likely to suffer a recur-
rent parasitemia with P. vivax than older children or adults.
Although this difference was not apparent for P. falciparum
infections, this may reflect the low failure rates with P. falcip-
arum and the fact that only 16% of the patients recruited in our
study were under 5 years of age. Hence our study may simply
have been underpowered in this respect. The clinical implica-
tions of this may be more apparent in areas of high transmis-
sion, where nearly all of the patients seeking medical treatment
are young children. Indeed cure rates for Rwanda suggest that
the efficacy of DHP in this age group may be significantly lower
than that observed in Asia (10).
Most formal pharmacokinetic studies of antimalarial drugs
are conducted either with healthy volunteers or adults. Since
pharmacokinetic profiles in children and pregnant women can
be markedly different, the derivation of appropriate dosing
recommendations necessitates that prospectively designed
pharmacokinetic studies be conducted with the target popula-
tion rather than extrapolated from studies with adults. Re-
cently this has been highlighted in a study of the use of sulfa-
doxine-pyrimethamine which suggests that this widely
deployed drug has systematically been underdosed in children
for over 20 years (2). Our preliminary findings raise the pos-
sibility that a similar discrepancy may arise with DHP and that
the currently recommended dose in children (2.25 mg/kg di-
hydroartemisinin and 18 mg/kg piperaquine) is suboptimal and
accounts for approximately 20% of treatment failures. How-
ever, formal pharmacokinetic studies are needed to confirm
our findings and define the relationship between the day 7
piperaquine concentration and the complete pharmacokinetic
profile.
Concerns have been raised over the stability of the dihydro-
artemisinin component in the fixed-dose combination (8). Re-
assuringly, over the 16-month duration of the study, despite
using the same batch of drugs there was no discernible change
or temporal trend in the early or late treatment responses.
Further studies are needed to confirm the clinical relevance of
tablet stability, but in practice the DHP appears to retain
excellent efficacy in a tropical rural setting.
In summary DHP is a well-tolerated and effective antima-
larial that results in excellent treatment outcome both in curing
initial infections with multidrug-resistant P. falciparum and P.
vivax and preventing reinfection and relapse. Using current
recommendations, health workers should aim to give a total of
at least 48 mg/kg of piperaquine. Further studies are warranted
to define the pharmacokinetic profile of piperaquine in chil-
dren and determine whether increased dosing can optimize the
efficacy of this important antimalarial combination regimen.
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